Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.

ABSTRACT:

Background

HIV-associated neurocognitive disorder (HAND) remains highly prevalent despite effective anti-retroviral therapy (ART). A number of adjunctive pharmacotherapies for HAND have been studied with disappointing results, but preliminary data suggest that lithium may provide clinical benefit. In addition, the low cost of lithium would facilitate access in low- and middle-income countries which carry the greatest burden of HIV.

Methods

Our objective was to evaluate the 24-week efficacy and safety of lithium in patients with moderate to severe HAND. Our primary efficacy endpoint was the change in Global Deficit Score (GDS) from baseline to 24 weeks, whereas our secondary endpoint was the change in proton magnetic resonance spectroscopy (H-MRS) brain metabolite concentrati

SUBMITTER: Decloedt EH 

PROVIDER: S-EPMC5120936 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature